S107 is a RyR-selective 1,4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.

S119-8 is a novel broad spectrum inhibitor of influenza virus replication (IC50=1.43 nM) by targeting the viral Nucleoprotein (NP), with no detectable cytotoxicity (CC50>50 uM).

S130 (ATG4B inhibitor S130) is a potent, specific ATG4B inhibitor with IC50 of 3.24 uM, shows strong affinity (Kd=4 uM) and specifically suppresses the activity of ATG4B, but not other proteases.

S-18986 is an orally bioavailable and BBB penetrant positive allosteric modulator of AMPA receptors.

S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.

S1P1 Agonist 8 is a potent, selective, orally bioavailable S1P1 receptor agonist with EC50 of 35 nM (S1P1 internalization), >100-fold selectivity over against receptor subtypes S1P2-5.

S-2101 is a potent lysine-specific demethylase 1 (LSD1) inhibitor with Ki of 0.61 uM.

S29434 (S 29434) is a highly potent, selective, cell-active inhibitor of Quinone reductase 2 (QR2) with IC50 of 5-16 nM, shows good selectivity for QR2 over QR1.

S-3448 is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.68 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

S3I-M2001 (Bromohydroxyacetone phosphate) is an oxazole-based peptidomimetic of the STAT3 SH2 domain-binding phosphotyrosine peptide that selectively disrupts active STAT3:STAT3 dimers.

S44563 is a potent, dual Bcl-2/Bcl-XL inhibitor with IC50 of 131 and 140 nM, respectively.

S44819 (S 44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2).

S55746 hydrochloride is a potent, orally active and selective BCL-2 inhibitor, with Kis and Kds of 1.3 nM, 520 nM and 3.9 nM, 186 nM for BCL-2 and BCL-XL, respectively. S55746 hydrochloride has antitumor activity.

S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity[1].

S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM.

S6K-18 is a highly selective inhibitor of S6K1, with an IC50 of 52nM.

S-99 inhibits LPS-induced TNFa release assay in vivo

SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.

sAJM-589 is a novel, potent small molecule Myc inhibitor that disrupts the Myc-Max leucine-zipper heterodimer with IC50 of 1.8 uM.

SAK3 (T-VGCC enhancer SAK3) is a potent, orally acitve enhancer of T-type voltage-gated Ca2+ channel (T-VGCC), enhances CaV3.1 and CaV3.3, but not CaV3.2 activity at concentrations of 0.01-10 nM in neuro2A cells in vitro.